You probably know melatonin as the hormone that helps you fall asleep. What you probably do not know is that your hair follicles produce their own melatonin, express melatonin receptors, and appear to use this molecule for functions that have nothing to do with your circadian rhythm. A growing body of research suggests that topical melatonin applied directly to the scalp can increase the number of actively growing hairs, particularly in women with androgenetic alopecia and diffuse thinning. The effect is subtle and the evidence is still early, which makes objective tracking essential. BaldingAI captures density changes that are too gradual for the mirror, giving you real data over the six-month window the research protocols require.
TL;DR
- Hair follicles synthesize melatonin locally and express melatonin receptors, independent of the pineal gland.
- In a small placebo-controlled pilot trial, Fischer et al. (2004) found that topical melatonin applied for six months increased the anagen hair rate in women with androgenetic or diffuse alopecia. Larger open-label studies of a 0.0033% solution followed in 2012.
- Melatonin acts as a potent antioxidant at the follicle and may modulate androgen receptor expression, extending the anagen growth phase.
- The evidence is for topical application, not oral melatonin taken for sleep. No systemic sedation was reported in clinical trials.
- Track for a minimum of six months before evaluating. Small effect sizes require objective measurement.
Important
This article is educational and not medical advice. If you are worried about sudden shedding, scalp symptoms, or side effects, talk to a licensed clinician.
Why do hair follicles care about melatonin?
Melatonin is best known as the pineal gland's signal for darkness, the molecule that tells your body it is time to sleep. But melatonin production is not limited to the brain. Human skin is a significant extrapineal source of melatonin, and hair follicles are among the most active producers. Research by Kobayashi et al. (2005) in The FASEB Journal showed that mouse and human hair follicles make melatonin, at levels far above those in the blood, and express melatonin receptors.
This local production suggests melatonin plays a direct role in follicular biology that goes beyond sleep regulation. At the follicle level, melatonin acts as one of the most potent endogenous free radical scavengers known. Oxidative stress is a recognized contributor to follicle miniaturization and premature entry into the catagen (regression) phase. By neutralizing reactive oxygen species at the follicular level, melatonin may help protect the dermal papilla cells that drive hair growth.
The mechanism: antioxidant protection plus androgen modulation
Melatonin's relevance to hair loss rests on two pathways. The first is its antioxidant capacity. Unlike most antioxidants, melatonin is amphiphilic, meaning it can cross cell membranes and scavenge free radicals in both lipid and aqueous environments. It also upregulates other antioxidant enzymes (superoxide dismutase, glutathione peroxidase), creating a cascade effect that amplifies its protective reach.
The second proposed pathway involves androgen signaling. Some researchers have suggested that melatonin may modulate androgen receptor expression in hair follicle cells, which could reduce the sensitivity of follicles to dihydrotestosterone (DHT), the primary androgen behind pattern hair loss. This has not been confirmed in human trials. This is a different mechanism than DHT blockers like finasteride, which reduce DHT production upstream. Melatonin may instead make the follicle less responsive to the DHT that is already present.
Both pathways converge on the same practical outcome: extended time in the anagen growth phase and delayed transition to catagen and telogen. In a follicle under androgenetic stress, that extension could mean the difference between a hair that reaches full terminal thickness and one that miniaturizes prematurely.
What does the clinical evidence show?
The clinical data comes mainly from two papers. Fischer et al. (2004), published in the British Journal of Dermatology, was a double-blind, placebo-controlled pilot trial in 40 women with androgenetic or diffuse alopecia, who applied a 0.1% melatonin solution or a placebo to the scalp for six months. Fischer et al. (2012), published in the International Journal of Trichology, then reported five studies of a cosmetic solution containing 0.0033% melatonin, including a 3-month, open-label multicenter study of more than 1,800 men and women with androgenetic alopecia.
The results were notable. In the 2004 trial, melatonin significantly increased the anagen hair rate compared with placebo in occipital hair of women with androgenetic alopecia and in frontal hair of women with diffuse alopecia. In the 2012 multicenter study, the share of patients with a clearly positive hair-pull test fell from 61.6% to 7.8% over three months. A smaller 2012 study in 35 men measured higher hair density after three and six months. These later studies had no placebo group.
The 2012 report described safety and tolerability as good across all five studies, and once-daily evening application did not significantly change serum melatonin levels.
In a 2018 formulation study by Hatem et al. (2018) in Expert Opinion on Drug Delivery, melatonin packed into nanostructured lipid carriers gave better results than a plain melatonin solution in patients with androgenetic alopecia, with higher hair density and thickness and less hair loss.
Topical vs. oral: an important distinction
If you already take oral melatonin for sleep, you might assume it offers the same follicular benefit. The evidence does not support that assumption. The clinical research on melatonin for hair loss focuses exclusively on topical application directly to the scalp. Oral melatonin undergoes significant first-pass metabolism in the liver, and the amount that reaches scalp follicles systemically is likely negligible compared to direct topical delivery.
That said, oral melatonin may have indirect benefits for hair health through its effects on sleep quality and stress reduction. Chronic sleep deprivation raises cortisol, which can push follicles into telogen prematurely. Improving sleep is broadly beneficial for hair maintenance, but that is a systemic effect, not a targeted follicular one.
What products are available?
Topical melatonin for hair loss is not as widely available as minoxidil, and regulatory status varies by country. Asatona is a cosmetic topical melatonin solution available in parts of Europe, formulated at the same low concentration used in the 2012 Fischer et al. studies. Follow the label or your pharmacist on how to use it, and log the time of day you apply it.
Some compounding pharmacies in the US and Europe can prepare custom melatonin scalp formulations, often combined with other actives like minoxidil or caffeine. If you go this route, the strength is a decision for the prescriber and pharmacist, so log the exact concentration on the label. The 2012 Fischer studies tested a very low concentration. The follicular receptors are highly sensitive, and more is not necessarily better with topical melatonin.
Over-the-counter melatonin-containing hair serums have started appearing from cosmetic brands, but few disclose their melatonin concentration. If the label does not specify a percentage, you cannot log the strength or compare it with what was tested clinically.
Who might benefit most?
The strongest evidence is in women with androgenetic alopecia or diffuse thinning. The only placebo-controlled trial, Fischer et al. (2004), enrolled only women, and in one of the later open studies hair loss fell in women but stayed the same in men. For women who cannot use finasteride (it is contraindicated in women of childbearing age) and want something beyond minoxidil, topical melatonin is one of the few options with published clinical data.
For men, topical melatonin is more likely to be useful as an adjunct than as a standalone treatment. If you are already on finasteride and minoxidil and want to build a more complete treatment stack, melatonin adds a distinct mechanism (antioxidant protection, plus a proposed effect on androgen signaling) that does not overlap with your existing treatments.
Anyone with a high oxidative stress load, whether from chronic inflammation, poor sleep, intense training, or environmental exposures, may also stand to benefit from melatonin's antioxidant properties at the follicle. Oxidative damage to follicular cells is an underappreciated factor in hair loss progression.
Safety and side effects
The safety profile of topical melatonin is reassuring. In the 2012 Fischer et al. report, once-daily application of the 0.0033% solution did not significantly change serum melatonin levels, and tolerability was good across studies that included more than 1,800 people. In the 2004 trial, blood melatonin rose under treatment but stayed within the normal night-time peak. Drowsiness from scalp application is therefore unlikely.
The published studies reported good tolerability, and no drug interactions have been documented for topical melatonin at cosmetic concentrations. This makes it one of the lower-risk options available for hair loss treatment.
Limitations you should know about
The evidence for topical melatonin is promising but early. The large 2012 Fischer et al. multicenter study was open-label, not a randomized placebo-controlled trial. That design cannot rule out placebo effect or observer bias. The only placebo-controlled trial, from 2004, enrolled 40 women. Sample sizes in other melatonin-for-hair studies are small, long-term data beyond 12 months is scarce, and no head-to-head comparisons with minoxidil or finasteride exist.
Product availability remains limited. Asatona is not sold in every market, compounding pharmacies add cost and complexity, and many OTC “melatonin hair serums” do not disclose whether they contain a clinically relevant concentration. Regulatory status varies: melatonin is an OTC supplement in the US but a prescription medication in parts of Europe and Australia.
How to track your melatonin response
If you decide to try topical melatonin, commit to the same six-month tracking window used in the 2004 Fischer et al. trial. Hair responds slowly to any intervention. The hair growth cycle means that a follicle pushed into anagen today may not produce a visible hair for three to four months.
Start with a baseline scan on day one: hairline, temples, crown, and part line. Use consistent lighting and angle at every session. BaldingAI standardizes these variables so each scan produces a comparable density score. Scan every one to two weeks and log your melatonin product, concentration, and application frequency alongside each photo.
At the six-month mark, review your trend line. A stable or upward density trajectory is a positive signal. Because melatonin's effect size is likely modest, the difference between “working” and “not working” may be invisible in the mirror but clearly visible in your density data. That objectivity is what lets you make informed decisions about whether to continue, adjust, or add other treatments.
The bottom line
Melatonin for hair loss is not a fringe idea. Hair follicles produce it, respond to it, and appear to benefit from it when it is applied topically at low concentrations. The clinical data shows a real signal, particularly in women with androgenetic alopecia and diffuse thinning. The mechanism is biologically distinct from finasteride and minoxidil, which makes it a logical addition to a multi-treatment approach.
The caveats are real: the largest study was not placebo-controlled, the placebo-controlled trial was small, and product availability is inconsistent. But the safety profile is excellent, the cost is manageable, and the risk of trying it is close to zero. The only requirement is that you track the outcome with enough discipline to know whether it is actually helping. Six months of consistent scans will give you a clear answer.
Sources: Fischer et al. 2012, International Journal of Trichology, Fischer et al. 2004, British Journal of Dermatology, Hatem et al. 2018, Expert Opinion on Drug Delivery, Kobayashi et al. 2005, The FASEB Journal.
